Cerevel Therapeutics Holdings, Inc. (CERE)
|Net Income (ttm)||n/a|
|Trading Day||January 26|
|Day's Range||12.79 - 14.46|
|52-Week Range||9.82 - 18.27|
Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced ...
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced ...
Cerevel Therapeutics Holdings operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a P... [Read more...]
Dr. N. Anthony Coles Jr.
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for CERE is 22.33, which is an increase of 69.81% from the latest price.